| |
|
2026 |
|
2025 |
| |
|
£ |
£ |
|
£ |
£ |
| Fixed assets |
|
|
4,678 |
|
|
15,845 |
| Current assets |
|
32,907 |
|
|
28,063 |
|
| Creditors: amount falling due within one year |
|
(8,214) |
|
|
(3,225) |
|
|
Net current assets
|
|
|
24,693
|
|
|
24,838
|
|
Total assets less current liabilities
|
|
|
29,371 |
|
|
40,683 |
| Provisions for liabilities |
|
|
37 |
|
|
(464) |
|
Net assets
|
|
|
29,408 |
|
|
40,219 |
| |
|
|
|
|
|
|
|
Capital and reserves
|
|
|
29,408 |
|
|
40,219 |
| |
NOTES TO THE ACCOUNTS
General Information
ASCLEPIUS MEDICARE LTD is a private company, limited by shares, registered in England and Wales, registration number 13553984, registration address 34 Camden Street, Walsall, West Midlands, WS1 4HF.
The presentation currency is £ sterling.
| 1. |
Accounting policies
Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention.
The financial statements are prepared in sterling which is the functional currency of the company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
| Fixtures and Fittings |
25% Straight Line
|
| Motor Vehicles |
25% Straight Line
|
|
| 2. |
Tangible fixed assets
| Cost or valuation |
Motor Vehicles |
|
Fixtures and Fittings |
|
Total |
| |
£ |
|
£ |
|
£ |
| At 01 September 2025 |
15,858 |
|
28,809 |
|
44,667 |
| Additions |
- |
|
- |
|
- |
| Disposals |
- |
|
- |
|
- |
| At 31 August 2026 |
15,858 |
|
28,809 |
|
44,667 |
| Depreciation |
| At 01 September 2025 |
7,599 |
|
21,223 |
|
28,822 |
| Charge for year |
3,964 |
|
7,203 |
|
11,167 |
| On disposals |
- |
|
- |
|
- |
| At 31 August 2026 |
11,563 |
|
28,426 |
|
39,989 |
| Net book values |
| Closing balance as at 31 August 2026 |
4,295 |
|
383 |
|
4,678 |
| Opening balance as at 01 September 2025 |
8,259 |
|
7,586 |
|
15,845 |
|
| 3. |
Average number of employees
Average number of employees during the year was 2 (2025 : 2).
|
For the year ended 31 August 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the board of directors on 21 September 2026 and were signed on its behalf by: --------------------------------
Dr. Muhammad Umair Chaudhry
Director |
1
|